Workflow
美诺华: 宁波美诺华药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告

Group 1 - The company aims to improve the efficiency of idle fundraising through cash management, which will not affect the development of its main business [2][3] - The total amount used for cash management is 100 million yuan [2] - The funds come from the proceeds of a public offering of convertible bonds, totaling approximately 512.7 million yuan, which were fully received by January 20, 2021 [2] Group 2 - The company has purchased fixed-rate large-denomination time deposits from China Merchants Bank, which are considered low-risk investment products [6][7] - The cash management will not impact the implementation progress of fundraising projects [3][6] - The company has received approval from its shareholders for the cash management plan, ensuring compliance with internal control requirements [6][8] Group 3 - The company has made several purchases of large-denomination time deposits, including 10 million yuan in various tranches, with expected annualized returns ranging from 2.15% to 3.30% [4][5] - The cash management strategy is designed to enhance the returns on idle funds without compromising the interests of shareholders, particularly minority shareholders [8] - The company will report the purchased financial products as "trading financial assets" on its balance sheet, with the income recognized as investment income [8]